VEGFA and glioblastoma: Although patients with newly diagnosed glioblastoma (GBM) who were treated with bevacizumab did not show increased survival in two recent studies [1,2], bevacizumab (BEV)—a humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF)—has become an indispensable chemotherapeutic treatment for patients with recurrent glioma [3,4].